Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Matinas BioPharma Holdings, Inc. (MTNB)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/09/2023 |
8-K
| Quarterly results|
Docs:
|
"Matinas BioPharma Holdings, Inc. Condensed Consolidated Balance Sheets June 30, 2023 December 31, 2022 ASSETS: Current assets: Cash and cash equivalents $ 9,743 $ 6,830 Marketable debt securities 12,770 21,933 Restricted cash – security deposit 50 50 Prepaid expenses and other current assets 1,437 5,719 Total current assets 24,000 34,532 Non-current assets: Leasehold improvements and equipment – net 2,103 2,091 Operating lease right-of-use assets – net 3,345 3,613 Finance lease right-of-use assets – net 24 30 In-process research and development 3,017 3,017 Goodwill 1,336 1,336 Restricted cash – security deposit 200 200 Total non-current assets 10,025 10,287 Total assets $ 34,025 $ 44,819 LIABILITIES AND STOCKHOLDERS’ EQUITY: Current liabilities: Accounts payable $ 604 $ 618 Accrued expens..." |
|
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/07/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/15/2023 |
DEL AM
| Form DEL AM - Delaying amendment: |
| 06/09/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 04/18/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/15/2023 |
8-K
| Quarterly results|
Docs:
|
"Matinas BioPharma Holdings, Inc. Consolidated Balance Sheets December 31, 2022 2021 ASSETS: Current assets: Cash and cash equivalents $ 6,830 $ 21,030 Marketable debt securities 21,933 28,592 Restricted cash – security deposit 50 50 Prepaid expenses and other current assets 5,719 1,321 Total current assets 34,532 50,993 Non-current assets: Leasehold improvements and equipment - net 2,091 1,538 Operating lease right-of-use assets - net 3,613 4,219 Finance lease right-of-use assets - net 30 23 In-process research and development 3,017 3,017 Goodwill 1,336 1,336 Restricted cash - security deposit 200 200 Total non-current assets 10,287 10,333 Total assets $ 44,819 $ 61,326 LIABILITIES AND STOCKHOLDERS’ EQUITY: Current liabilities: Accounts payable $ 618 $ 937 Accrued expenses and other liabil..." |
|
| 03/15/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 01/30/2023 |
8-K
| Investor presentation |
| 01/12/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 12/29/2022 |
8-K
| Quarterly results |
| 12/22/2022 |
4
| Matkovits Theresa (Chief Development Officer) has filed a Form 4 on Matinas BioPharma Holdings, Inc.|
Txns:
| Granted 625,000 options to buy
@ $0.53, valued at
$331.3k
|
|
| 12/22/2022 |
4
| Liu Hui (Chief Technology Officer) has filed a Form 4 on Matinas BioPharma Holdings, Inc.|
Txns:
| Granted 625,000 options to buy
@ $0.53, valued at
$331.3k
|
|
| 12/22/2022 |
4
| Kucinski Keith A (CFO) has filed a Form 4 on Matinas BioPharma Holdings, Inc.|
Txns:
| Granted 625,000 options to buy
@ $0.53, valued at
$331.3k
|
|
| 12/22/2022 |
4
| Jabbour Jerome D (President and CEO) has filed a Form 4 on Matinas BioPharma Holdings, Inc.|
Txns:
| Granted 1,988,300 options to buy
@ $0.53, valued at
$1.1M
|
|
| 12/22/2022 |
4
| Hoover Thomas (Chief Business Officer) has filed a Form 4 on Matinas BioPharma Holdings, Inc.|
Txns:
| Granted 475,000 options to buy
@ $0.53, valued at
$251.8k
|
|
| 12/22/2022 |
4
| Ferguson James J. III (Chief Medical Officer) has filed a Form 4 on Matinas BioPharma Holdings, Inc.|
Txns:
| Granted 625,000 options to buy
@ $0.53, valued at
$331.3k
|
|
| 11/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/16/2022 |
4
| WIKLER MATTHEW (Director) has filed a Form 4 on Matinas BioPharma Holdings, Inc.|
Txns:
| Granted 142,657 options to buy
@ $0.7268, valued at
$103.7k
|
|
| 11/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/02/2022 |
8-K
| Quarterly results |
| 11/02/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/21/2022 |
8-K
| Quarterly results |
| 09/22/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 09/13/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/11/2022 |
8-K
| Quarterly results |
| 07/05/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/12/2022 |
8-K
| Quarterly results |
|
|
|